Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $14.8MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hyep Ivan | Chief Financial Officer | Aug 10 '26 | Option Exercise | $3.79 | 12,500 | $47,372 | 142,355 | Aug 12 04:19 PM |
| Hyep Ivan | Chief Financial Officer | Aug 10 '26 | Sale | $27.97 | 12,500 | $349,591 | 129,855 | Aug 12 04:19 PM |
| Mazumdar Claire | Chief Executive Officer | Aug 10 '26 | Option Exercise | $3.79 | 10,000 | $37,898 | 372,152 | Aug 12 04:19 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.